Lilly’s Q1 Surge Fueled by New Oral GLP‑1, Aggressive M&A and Upsized 2026 Guidance

Lilly’s first‑quarter earnings call underscored a “robust” start to the year, with CEO Dave Ricks emphasizing that the company is “delivering strong revenue growth” while “advancing our pipeline across all four therapeutic areas.” Revenue climbed to $41.5 billion, a 56 % increase from Q1 2025, propelled primarily by the blockbuster duo of Mounjaro (tirzepatide) and Semaglutide‑based products, which together added more than $7 billion in sales.

The headline financial metrics were buoyed by a surge in volume despite a 7 % decline in U.S. list price, a trend Ricks described as “a different dynamic” for the obesity market where “out‑of‑pocket cost is a meaningful driver of volume.” Gross margin slipped one point to 82.6 % as lower prices weighed, but non‑GAAP performance margin rose seven points to 50 % thanks to the top‑line surge.

Non‑GAAP earnings per share jumped to $8.55, more than double the $3.34 reported a year earlier, after stripping out $0.52 of acquired R&D charges.

The quarter’s most market‑moving development was the FDA approval of Foundayo (orforgopron), the first oral GLP‑1 approved for obesity. Ricks highlighted that Foundayo “offers the benefits of GLP‑1 therapy in a pill form and can be taken at any time of day without food or water restrictions,” positioning it as a “new molecule, a new modality” that could open a billion‑patient market worldwide.

Within weeks of launch, the drug was stocked in over 12 telehealth platforms and secured commercial access with two of the three largest U.S. pharmacy‑benefit managers.

“Eight‑thousand prescribers have already written for Foundayo, a third of whom had never written an oral GLP‑1,” said Ilya Yuffa, President of Lilly USA. “Twenty‑thousand patients have been treated, and 80 % of those are new to class,” he added, underscoring the drug’s potential to pull new patients into obesity care. The company expects the Medicare GLP‑1 bridge program—capped at $50 per month—to begin by July 1, extending coverage to seniors through December 2027 and further expanding the addressable market.

Lilly also used the call to showcase a flurry of pipeline milestones. Positive Phase III data were announced for an atopic dermatitis IL‑13 inhibitor in children as young as six months, a BTK inhibitor (pertibrutinib) that outperformed a venetoclax‑based regimen in CLL, and a combination of ixekizumab with tirzepatide that delivered both skin clearance and ≥10 % weight loss in psoriasis patients.

In the cardiometabolic arena, the company reported that the ACHIEVE I trial confirmed Foundayo’s cardiovascular safety and a 16 % lower risk of major adverse cardiac events versus insulin glargine, with a pre‑planned analysis suggesting a 57 % survival advantage.

Strategic acquisitions were another theme. Lilly announced agreements to acquire Orna Therapeutics (in‑vivo CAR‑T for autoimmune disease), Syntessa Pharmaceuticals (excessive daytime sleepiness), Colonia Therapeutics (in‑vivo platform for multiple myeloma) and Ajax Therapeutics (next‑generation JAK inhibitors). “We expect to remain active in business development to complement our internal portfolio, while maintaining the discipline to create shareholder value,” Ricks said.

On the capital‑allocation front, the company returned $1.5 billion to shareholders via dividends and repurchased $2.4 billion of stock in Q1. The revised 2026 guidance now targets $82 billion to $85 billion in revenue—up $2 billion from the prior outlook—and a non‑GAAP EPS range of $35.50 to $37, reflecting the “strong underlying performance of Mounjaro and Semaglutide” and the anticipated contribution from Foundayo.

Analysts pressed management on pricing sensitivity and the impact of generic competition. Jeff Meacham of Citi asked how margins would fare under varied price scenarios. Ricks replied that “every time we reduce pricing, we see a pretty large expansion” in volume, noting that the obesity market is “more informational than price‑sensitive” and that fixed‑cost structures give the company latitude to absorb price concessions while still scaling.

Questions about international Mounjaro growth elicited a response from Patrik Jonsson, who noted that the drug now enjoys “market share above 53 % OUS” and that generic semaglutide in India appears to be “stimulating the growth in the overall obesity market,” yet Mounjaro’s prescriptions are “about 10 % higher” post‑generic entry, underscoring the dual‑agonist’s resilience.

The Q&A also explored the new “Lilly Employer Connect” platform, a pilot that offers employers a transparent pricing model for obesity medicines. Yuffa explained that the initiative aims to “create new options to get to guests with employers” and that while the selling cycle for 2026 has largely passed, the program could generate incremental uptake in the back half of the year and beyond.

Investor sentiment was reflected in the stock’s performance: Lilly shares rose 9.8 % in the session, narrowing the gap to the 52‑week high to 17.6 % below. The price jump came despite a YTD decline of 13 % and signals that the market is rewarding the company’s execution and the promise of Foundayo’s launch.

Overall, Lilly’s Q1 results illustrate a company leveraging a diversified portfolio, a breakthrough oral obesity therapy, and a disciplined acquisition strategy to sustain double‑digit growth. The firm’s ability to convert pricing pressure into volume gains, expand access through Medicare and employer channels, and deliver a pipeline replete with late‑stage data positions it for continued outperformance, provided that regulatory reviews for Foundayo’s diabetes indication and international GLP‑1 approvals stay on track.